• Biogen research chief says 'misinformation' is cause for controversy surrounding Alzheimer's drug

    2 days ago - By Daily Mail

    Biogen R&D chief says that misinformation is at the heart of the controversy surrounding Aduhelm, his companies newly approved Alzheimer's drug.
    Read more ...